The Subcohort of patients who were on these statins prediagnostically had significantly higher tumour MCT1 expression than non-statin users (P = 0.02), 42% of statin users had high MCT1 expression versus only 16% in non-users and MCT4 expression was not significantly different between the two groups (P = 0.19) confirming that statin use is associated with an upregulation of only MCT1 expression in HNSCC tumours (Table 1). This evidence concerns the gene SLC16A1 and neoplasm.